Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF

Objectives: The authors sought to examine the effect of dapagliflozin across the spectrum of risk in patients enrolled in DAPA-HF. Background: In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decrease...

Full description

Bibliographic Details
Main Authors: Bengtsson, O. (Author), DAPA-HF Investigators and Committees (Author), Docherty, K.F (Author), Inzucchi, S.E (Author), Jhund, P.S (Author), Køber, L. (Author), Kosiborod, M.N (Author), Langkilde, A.M (Author), Lindholm, D. (Author), Martinez, F.A (Author), McMurray, J.J.V (Author), Ponikowski, P. (Author), Sabatine, M.S (Author), Simpson, J. (Author), Sjöstrand, M. (Author), Solomon, S.D (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
Online Access:View Fulltext in Publisher